Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma
|
|
- Irene Melton
- 5 years ago
- Views:
Transcription
1 Med. J. Cairo Univ., Vol. 84, No., December: , 6 Prognostic Value of Early Introduction of Second Line in Patients with Diffuse Large B Cell Lymphoma HAMDY M. ZAWAM, M.D.; MENNAT ALLAH M.M. ABD EL-RADI, M.Sc. and EMAD M. HAMMADA, M.D. The Department of Clinical Oncology, Faculty of Medicine, Cairo University Abstract Introduction: Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL). Although potentially curable, 4% of patients with DLBCL will die of relapsed or refractory disease. Many studies proved the correlation between achievement of early response to treatment and better survival. Our study aims to assess the prognostic of early introduction of second line chemotherapy. Methods: Randomized pilot trial of 5 adult patients with DLBCL conducted at Kasr Al-Ainy Oncology Department, ages 8-65 years, pathologically proven as DLBCL stages IIB-IV according to Ann Arbor classification, ECOG performance status <3. Patients were treated with standard dose 3- weekly R-CHOP for 3 cycles. Those achieved partial remission were randomized to either continue R-CHOP () or to shift to R-ESHAP (). Results: Fifty patients were enrolled between May 3 and September 4. Median age was 5 years. Better outcome with non shift group (response rate=9.9% Vs 66.67%). The month disease free survival in was 75% while in was 58% (=.49). The month overall survival was % in versus 68% in ( =.3). Conclusion: These results should be confirmed on larger scale studies. Key Words: DLBCL Early second line. Introduction DIFFUSE Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin Lymphoma (NHL). It accounts for 3%-4% of all adult NHLs []. NHL was ranked as 5 th most frequent cancer in Egypt []. Although potentially curable, 4% of patients with DLBCL will die of relapsed or refractory disease. The standard of care for initial treatment Correspondence to: Dr. Hamdy M. Zawam, The Department of Clinical Oncology, Faculty of Medicine, Cairo University of DLBCL is R-CHOP- (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, prednisone on a -day schedule) []. Many studies proved the correlation between achievement of early response to treatment and better survival parameters in patients with DLBCL [3]. For patients with inadequate response at the interim treatment response evaluation, enrolment in a clinical trial including more intensified regimens is an option [4]. Early introduction of salvage therapy may allow restoring the chemo-sensitivity of the disease, saving the patient from ineffective therapy and may overcome the emerging resistant clones and, hence to improve the overall response. This represented the rationale of our study. Accordingly, our study aimed to assess the benefit of using intensified regimen (ESHAP) for patients with DLBCL having partial response at interim response evaluation. Patients and Methods This prospective randomized pilot trial included 5 patients with a proven pathological diagnosis of DLBCL presented to Kasr Al-Ainy Clinical Oncology Department during the period from May 3 till September 4. The study was conducted in accordance with the International Conference on Harmonization for Good Clinical Practice guidelines and the ethical principles outlined in the Declaration of Helsinki. All patients provided written, informed consent before undergoing any study-related procedures. Eligible patients were those with DLBCL stage IIB-IV according to Ann Arbor classification were candidate to receive immune-chemotherapy. The 443
2 444 Prognostic Value of Early Introduction of Second Line in Patients with DLBCL age range for 8-65 years, with ECOG performance status <3. The following data were collected from all recruited patients: History of smoking, and thorough physical examination including blood pressure, node bearing areas, performance status and constitutional manifestations. Laboratory assessment: Differential CBC, serum LDH, serum B macroglobulin levels, Uric acid, HBsAg and HCV antibody testing. Immunophenotyping: CD, CD45, CD3, CD5 at least. CT chest, abdomen and pelvis at the start and after 6 months. BM aspirate and biopsy. Lumbar puncture if indicated (high risk for CNS disease). All patients received the standard R-CHOP regimen every 3 weeks. Response was assessed after three cycles by CT scan of chest, abdomen and pelvis. Patients with negative scan (CR) completed six cycles of R-CHOP. Those with partial remission, were randomized into groups: continued R-CHOP and received second line chemotherapy R- ESHAP. Toxicity assessment: Every patient was assessed each cycle for toxicity and reported according to NCI-CTCAE v4. Statistical methods: All data were tabulated and statistically studied by descriptive analysis as well as survival analysis in relation to different prognostic factors. Comparison between the two groups was done using student test for continuous data and CHI square (χ) test for categorical data. Survival analysis was done according to Kaplan- Meier method and compared by log-rank test for significance. Univariate analysis using cox regression module was performed to test the power of relation between the independent variables and survival differences were considered significant if was less than.5. Results Of 5 patients included in the study, patients achieved partial remission after 3 cycles of R- CHOP and were eligible for randomization Fig. (). Eleven patients were randomized to (continue R-CHOP); while 9 patients were randomized to (shift to R-ESHAP), 5 of them did not to receive Rituximab due financial issues. Comparing the groups regarding the baseline characteristics, there was no statistical significant difference (Table ). Response evaluation: Comparing the randomized groups, the response rate for was 9.9% (/) while in it was 66.67% (3/9) with statistically significant difference ( p=.3). By comparing the factors affecting the response, the only contributing factor for response rate was the treatment regimen (Table ). Comparing factors affecting response rate at first assessment after 3 cycles of R-CHOP (CR and PR) including age, gender, ECOG performance status, bone marrow involvement, site of disease, IPI score, bulk of disease and stage; only disease stage was the only significant contributing factor for earlier and better response. Survival evaluation: At a median follow-up period of 6.3 months, year DFS in was 75% while in Group B was 58% which was statistically significant ( =.49). The year OS was % in Group A versus 68% in which was statistically significant (=.3). The median time to CR in was 7 weeks (-7), while in, the median time was 3 weeks (9-) (=). Toxicity evaluation: The grade 3 and 4 adverse events were consistent with the expected toxic effects of utilized regimens. Grade - fatigue and grade - vomiting are the most encountered toxicities, following total alopecia (was nearly universal after cycles of R- CHOP). Eight patients out of 5 patients (6%) experienced neutropenic fever along treatment course. One patient out of 5 patients (%) developed septic shock. One patient (%) developed neutropenic fever due to bacterial chest infection 3 times. Four patients (8%) developed neutropenic fever once. (4 received R-CHOP and 4 received ES- HAP+/-R).
3 Hamdy M. Zawam, et al. 445 Four patients developed grade 3 paraesthesia of both hands and feet. One patient (%) experienced it by the fifth cycle of R-CHOP. Two patients out of 5 patients (4%) developed asymptomatic scattered macular eruptions after second cycle R-CHOP. One patient out of 5 patients (%) developed scattered erythema with pruritis twice along he treatment course with R- CHOP. Two diabetic patients developed hyperglycemia needed increasing insulin doses in ESHAP group. Symptomatic hypocalcemia (<7) was seen in cases. Two out of nine patients (%) developed hypokalemia (.3-.7) after the second cycle of ESHAP despite the supplementations during treatment. Partial remission ( patients) Adult patients diagnosed with DLBCL (5 patients) Complete remission (9 patients) Continued on RCHOP ( patients) Shifted to R-ESHAP (9 patients) Progressed ( patient) Fig. (): Schematic presentation of results of a prospective study of 5 adult patients with DLBCL (NEMROCK). Cum survival R-ESHAP=9 patients R-CHOP= patients mo DFS=75% Vs 58% p= DFS ttt Group -Censored -Censored Fig. (): The difference in DFS between A & B groups (N= patients). Cum survival R-ESHAP=9 patients mo OS=% Vs 68% p=.3 R-CHOP= patients OS Fig. (3): The difference in OS between A & B groups (N= patients). Table (): General characteristics of partial responders (N=). Items Age: <4 4-6 >6 (N=) Gender: Female Male 7 PS: ttt Group -Censored -Censored Bm: Normal High 7 5 LDH: Normal 3.33 High 8 8 B symptoms: No Yes 4 5 Bulky: No 7.79 >=cm Yes Stage: Early Advanced 8 6 Site: Nodal Extranodal 3 BM infiltration: ve ve IPI score: Very good.9 Good 5 5 Poor 6 3 HCV: Negative Positive 3 4 HBV: Negative 9.33 Positive
4 446 Prognostic Value of Early Introduction of Second Line in Patients with DLBCL Table (): Patterns of response in patients randomized to R- CHOP or R-ESHAP. Items Complete remission Partial remission Stationary or refractory disease (N=) Table (3): Comparison of toxicity between different groups of response. Parameter (N=) Liver enzymes: No 9.56 Yes Neutrpenia: Nausea: Fatigue: Vomiting: Mucositis: Neuropathy: 7.76 Hypokalemia: No 7.9 Yes NF 4. Discussion The rationale of using early second line has been utilized by Sehn et al., in 4 who used PET scan to categorize the patients to early salvage by R-ICE. In spite of that, the response rate was 59% similar to our study and therefore the chemoimmunotherapy will not be enough to improve the action in partial responding cases. This study was conducted at Kasr Al-Ainy Oncology Department between May 3 and September 4. Fifty patients with DLBCL were recruited fulfilling the previously mentioned inclusion criteria. The main aim in this study was to assess the possibility of improving the prognosis of patients with DLBCL through early introduction of second line R-ESHAP, a non-cross resistant regimen for patients not achieving CR after third cycle. The initial CR rate to R-CHOP (after 3 cycles) in this study was 58% which is similar to that in other trials [3,5]. This consistency might be due to high IPI score that was found in our study and Sehn et al., 4 (44% and 4% respectively). The results of treatment with R-CHOP (for partially responding cases) appear to be better than ESHAP. The majority of patients in ESHAP cases did not receive rituximab (administrative problems). This seems to be the main factor behind the inferior results of ESHAP. Furthermore, larger scale studies will allow us to obtain a firm conclusion regarding which regimen is more effective. In Coral study, patients with DLBCL in first relapse or who were refractory after first line therapy were randomly assigned to either R-DHAP or R-ICE to be followed by ASCT for responding patients. The overall response rate was 63% with CR rate of only 4%. The results of ESHAP (even without rituximab) in our trial (CR 66%) are comparable to the results of R-ICE or R-DHAP in Coral trial (CR 4%). The month OS in the R-CHOP group was superior to that of ESHAP group which may be comparable to what is reported by Herbrecht et al., (3) study (the 3 year OS of R-CPOP 69% versus 84% of R-CHOP with p=.9) [6]. Compared to bortezomib plus R-CHOP in which mo OS was >8% [7] versus 64.7% for ESHAP +/-R in this study. Again despite poorer risk factors in Ruan et al., rendering ESHAP ± R a poorer option [7]. Another study done by P.J. Still et al., reported that upfront autotransplant improves PFS for responders in DLBCL patients, including those induced with CHOP-R, with a stronger outcome seen for those with High IPI where year OS was 8% [8]. This result is still higher than 64.7% in ESHAP use, but R-ESHAP is cheaper and more available with less side effects related to high dose therapy. The weakness in our study includes small sample size as well as the lack of molecular and cytogenetics based initial diagnosis to specify populations with poorer risk.
5 Hamdy M. Zawam, et al. 447 Among the adverse effects seen in both groups, grade III fatigue was statistically significant in which could be attributed to different mechanisms and effects of multiple drugs. Hypokalemia and hyperglycemia were seen in Group B due to cisplatin and higher doses of corticosteroids. Otherwise comparable adverse effects between the two randomized groups. One patient died of septic shock in this study versus 3 patients in GEL/TAMO study as R-ESHAP toxicity. While hypocalcemia and hypomagnesemia was encountered in % which is comparable to 5% in GEL/TAMO. These data might denote tolerability of Egyptians to R-ESHAP. As regard neuropathy % of patients who completed 6 cycles R-CHOP suffered grade III neuropathy versus 4% of patients who recieved bortezomib with R-CHOP regimen in Ruan et al., trial. No grade III neuropathy in ESHAP group [7]. Grade III and IV neutropenia was encountered in 33% of patients in ESHAP group versus 4% in bortezomib+r-chop study [7]. This makes ESHAP +/-R a more tolerable regimen. In conclusion, stage is an important factor affecting the initial response to chemotherapy; early introduction of a second line chemotherapy is not better than continuing R-CHOP which may be attributed to cumulative Doxorubicin dose efficacy. References - VAIDYA R. and WITZIG T.E.: Prognostic factors for diffuse large B-cell lymphoma in the R (X) CHOP era Annals of Oncology Advance, 4, accessed annonc. oxfordjournals.org/at Onco. Path. on October 5, 4. - AMAL S.I., HUSSEIN M., et al.: Cancer Incidence in Egypt: Results of the National Population-Based Cancer Registry Program, Journal of Cancer Epidemiology Volume, (4), Article ID 43797, HAIOUN C., LTTI ERAHMOUNI A., et al.: 8 fluoro- -deoxy-d-glucose positron emission tomography (FDG- PET) in aggressive lymphoma; an early prognostic tool predicting patient outcome. Blood, 6: 376-8, NCCN guidelines, version., National Comperehensive Cancer Network SEHN L.H., HARDY E.L.G., GILL K.K., et al.: Connors: 39 Phase Trial of Interim PET Scan-Tailored Therapy in Patients with Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC), ASH HERBRECHT R., CERNOHOUS P., ENGERT A., et al.: Comparison of pixantrone-based regimen (CPOP-R) with doxorubicin-based therapy (CHOP-R) for treatment of diffuse large B-cell lymphoma Annals of Oncology 4, (): 68-3, RUAN J., MARTIN P., FURMAN R.R., et al.: Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J. Clin. Oncol., 9: 69-7,. 8- STILL P.J., UNGER J.M., COOK J., et al.: Randomized phase III U.S./Canadian intergroup trial (SWOG S974) comparing CHOP±R for eight cycles to CHOP±R for six cycles followed by autotransplant for patients with highintermediate (H-int) or high IPI grade diffuse aggressive non-hodgkin lymphoma, Journal of Clinical Oncology, Vol. 9, abstract a8,.
Update: Non-Hodgkin s Lymphoma
2008 Update: Non-Hodgkin s Lymphoma ICML 2008: Update on non-hodgkin s lymphoma Diffuse Large B-cell Lymphoma Improved outcome of elderly patients with poor-prognosis diffuse large B-cell lymphoma (DLBCL)
More informationInterim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience
Interim PET in Diffuse Large B Cell Lymphoma.The GEL/TAMO experience MD. Caballero, Hospital Universitario, Salamanca, Spain. Chair of The GEL/TAMO Group Menton,9 april 2010 Disclosures for Dolores Caballero
More informationStrategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL
New Evidence reports on presentations given at ASH 2009 Strategies for the Treatment of Elderly DLBCL Patients, New Combination Therapy in NHL, and Maintenance Rituximab Therapy in FL From ASH 2009: Non-Hodgkin
More informationWhat are the hurdles to using cell of origin in classification to treat DLBCL?
What are the hurdles to using cell of origin in classification to treat DLBCL? John P. Leonard, M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical
More informationNON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: INDOLENT Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and Dr.
More informationDisclosures for Dr. Peter Borchmann 48 th ASH Annual meeting, Orlando, Florida
Phase II Study of Pixantrone in Combination with Cyclophosphamide, Vincristine, and Prednisone (CPOP) in Patients with Relapsed Aggressive Non-Hodgkin s Lymphoma P Borchmann Universitaet de Koeln, Koeln,
More informationBendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma
Bendamustine, Bortezomib and Rituximab in Patients with Relapsed/Refractory Indolent and Mantle-Cell Non-Hodgkin Lymphoma Friedberg JW et al. Proc ASH 2009;Abstract 924. Introduction > Bendamustine (B)
More informationNON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary)
NON HODGKINS LYMPHOMA: AGGRESSIVE Updated June 2015 by Dr. Manna (PGY-5 Medical Oncology Resident, University of Calgary) Reviewed by Dr. Michelle Geddes (Staff Hematologist, University of Calgary) and
More informationRituximab in the Treatment of NHL:
New Evidence reports on presentations given at ASH 2010 Rituximab in the Treatment of NHL: Rituximab versus Watch and Wait in Asymptomatic FL, R-Maintenance Therapy in FL with Standard or Rapid Infusion,
More informationSupplementary Appendix to manuscript submitted by Trappe, R.U. et al:
Supplementary Appendix to manuscript submitted by Trappe, R.U. et al: Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful
More information2012 by American Society of Hematology
2012 by American Society of Hematology Common Types of HIV-Associated Lymphomas DLBCL includes primary CNS lymphoma (PCNSL) Burkitt Lymphoma HIV-positive patients have a 60-200 fold increased incidence
More information12 th Annual Hematology & Breast Cancer Update Update in Lymphoma
12 th Annual Hematology & Breast Cancer Update Update in Lymphoma Craig Okada, MD, PhD Assistant Professor, Hematology January 14, 2010 Governors Hotel, Portland Oregon Initial Treatment of Indolent Lymphoma
More information2.07 Protocol Name: CHOP & Rituximab
2.07 Protocol Name: CHOP & Rituximab Indication Intermediate and high grade, B-cell non-hodgkins lymphoma expressing CD20. Second or third line therapy for low grade, B cell non- Hodgkins lymphoma expressing
More informationNon-Hodgkin lymphoma
Non-Hodgkin lymphoma Non-Hodgkin s lymphoma Definition: - clonal tumours of mature and immature B cells, T cells or NK cells - highly heterogeneous, both histologically and clinically Non-Hodgkin lymphoma
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationFOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting?
Indolent Lymphoma Workshop Bologna, Royal Hotel Carlton May 2017 FOLLICULAR LYMPHOMA: US vs. Europe: different approach on first relapse setting? Armando López-Guillermo Department of Hematology, Hospital
More informationLYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center
LYMPHOMA Joginder Singh, MD Medical Oncologist, Mercy Cancer Center Lymphoma is cancer of the lymphatic system. The lymphatic system is made up of organs all over the body that make up and store cells
More informationHead and Neck: DLBCL
Head and Neck: DLBCL Nikhil G. Thaker Chelsea C. Pinnix Valerie K. Reed Bouthaina S. Dabaja Department of Radiation Oncology MD Anderson Cancer Center Case 60 yo male Presented with right cervical LAD
More informationThe treatment of DLBCL. Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona
The treatment of DLBCL Michele Ghielmini Medical Oncology Dept Oncology Institute of Southern Switzerland Bellinzona NHL frequency at the IOSI Mantle Cell Lymphoma 6.5 % Diffuse Large B-cell Lymphoma 37%
More informationDiffuse Large B-Cell Lymphoma (DLBCL)
Diffuse Large B-Cell Lymphoma (DLBCL) DLBCL/MCL Dr. Anthea Peters, MD, FRCPC University of Alberta/Cross Cancer Institute Disclosures Honoraria from Janssen, Abbvie, Roche, Lundbeck, Seattle Genetics Objectives
More informationRADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA
RADIOIMMUNOTHERAPY FOR TREATMENT OF NON- HODGKIN S LYMPHOMA Pier Luigi Zinzani Institute of Hematology and Medical Oncology L. e A. Seràgnoli University of Bologna, Italy Slovenia, October 5 2007 Zevalin
More informationIndolent Lymphomas. Dr. Melissa Toupin The Ottawa Hospital
Indolent Lymphomas Dr. Melissa Toupin The Ottawa Hospital What does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with
More informationNew Targets and Treatments for Follicular Lymphoma
Winship Cancer Institute of Emory University New Targets and Treatments for Follicular Lymphoma Jonathon B. Cohen, MD, MS Assistant Professor Div of BMT, Emory University Intro/Outline Follicular lymphoma,
More informationDisclosures WOJCIECH JURCZAK
Disclosures WOJCIECH JURCZAK ABBVIE (RESEARCH FUNDING), CELGENE (RESEARCH FUNDING); EISAI (RESEARCH FUNDING); GILEAD (RESEARCH FUNDING); JANSEN (RESEARCH FUNDING); MORPHOSYS (RESEARCH FUNDING), MUNDIPHARMA
More informationWho should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University
Who should get what for upfront therapy for MCL? Kami Maddocks, MD The James Cancer Hospital The Ohio State University Treatment Challenges Several effective options, improve response durations, none curable
More informationDr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009
Treatment of DLBCL Dr. Nicolas Ketterer CHUV, Lausanne SAMO, May 2009 Non-hodgkin lymphomas DLBCL Most common NHL subtype throughout the world many other types of lymphoma with striking geographic variations
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationIndolent Lymphomas: Current. Dr. Laurie Sehn
Indolent Lymphomas: Current Dr. Laurie Sehn Why does indolent mean? Slow growth Often asymptomatic Chronic disease with periods of relapse (long natural history possible) Incurable with current standard
More informationAddition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
VOLUME 46 ㆍ NUMBER 2 ㆍ June 2011 THE KOREAN JOURNAL OF HEMATOLOGY ORIGINAL ARTICLE Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
More informationAddition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Original Article Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma Bo Jia 1, Yuankai Shi 1, Suyi Kang 1, Sheng
More informationAggressive Lymphomas - Current. Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre
Aggressive Lymphomas - Current Dr Kevin Imrie Physician-in-Chief, Sunnybrook Health Sciences Centre Conflicts of interest I have no conflicts of interest to declare Outline What does aggressive lymphoma
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationLYSA PET adapted programs. O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France
LYSA PET adapted programs O. Casasnovas Hematology department Hopital Le Bocage, CHU Dijon, France 3 phase III trials DLBCL LNH 09-1B: aaipi = 0, 18 80y : ongoing GAINED: aaipi = 1-3, 18 60y : ongoing
More informationCAR-T cell therapy pros and cons
CAR-T cell therapy pros and cons Stephen J. Schuster, MD Professor of Medicine Perelman School of Medicine of the University of Pennsylvania Director, Lymphoma Program & Lymphoma Translational Research
More informationLymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège. 14 th post-ash meeting, January 6 th 2011, Brussels
Lymphoma Christophe BONNET Centre Hospitalier Universitaire, Ulg, Liège 14 th post-ash meeting, January 6 th 2011, Brussels Hodgkin s lymphoma Follicular lymphoma Diffuse large B-cell lymphoma Mantle cell
More informationBendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
Bendamustine is Effective Therapy in Patients with Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma Kahl BS et al. Cancer 2010;116(1):106-14. Introduction > Bendamustine is a novel alkylating
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationModified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
ORIGINAL ARTICLE DOI: 10.3904/kjim.2010.25.3.301 Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma Changhoon Yoo
More informationWhat is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin
What is the best second-line approach to induce remission prior to stem cell transplant? Single agent brentuximab vedotin Alison Moskowitz, MD Assistant Attending, Lymphoma Service Memorial Sloan Kettering
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new NICE guidance is published. To view the latest
More informationFDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-hodgkin lymphoma
Original article Annals of Oncology 16: 1514 1523, 2005 doi:10.1093/annonc/mdi272 Published online 24 June 2005 FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationCPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults
MANAGEMENT IN CONFIDENCE CPAG Summary Report for Clinical Panel Policy 1630 Bendamustine-based chemotherapy for first-line treatment of Mantle cell lymphoma (MCL) in adults The Benefits of the Proposition
More informationMMAE disrupts cell division and triggers apoptosis. Pola binds to cell surface antigen CD79b. Pola is internalized; linker cleaves, releasing MMAE
Adding Polatuzumab Vedotin (Pola) to Bendamustine and Rituximab () Treatment Improves Survival in Patients With Relapsed/Refractory DLBCL: Results of a Phase II Clinical Trial Abstract S802 Sehn LH, Kamdar
More informationTargeted Radioimmunotherapy for Lymphoma
Targeted Radioimmunotherapy for Lymphoma John Pagel, MD, PhD Fred Hutchinson Cancer Center Erik Mittra, MD, PhD Stanford Medical Center Brought to you by: Financial Disclosures Disclosures Erik Mittra,
More informationLarge cell immunoblastic Diffuse histiocytic (DHL) Lymphoblastic lymphoma Diffuse lymphoblastic Small non cleaved cell Burkitt s Non- Burkitt s
Non Hodgkin s Lymphoma Introduction 6th most common cause of cancer death in United States. Increasing in incidence and mortality. Since 1970, the incidence of has almost doubled. Overview The types of
More informationPolicy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies
Policy for Central Nervous System [CNS] Prophylaxis in Lymphoid Malignancies UNCONTROLLED WHEN PRINTED Note: NOSCAN Haematology MCN has approved the information contained within this document to guide
More informationDiffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA
Diffuse Large B-Cell Lymphoma Front line Therapy John P. Leonard, MD Weill Cornell Medicine New York, New York USA Disclosures Consulting advice: Hospira, Bayer, Juno Therapeutics, Teva, Oncotracker, Gilead
More informationRituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's Lymphoma
Page 1 of 5 Home Search Study Topics Glossary Search Full Text View Tabular View No Study Results Posted Related Studies Rituximab and Combination Chemotherapy in Treating Patients With Non- Hodgkin's
More informationTime-to-treatment of diffuse large B-cell lymphoma in São Paulo
RAPID COMMUNICATION Time-to-treatment of diffuse large B-cell lymphoma in São Paulo Flávia Dias Xavier, I Debora Levy, II Juliana Pereira I I Hospital das Clínicas da Faculdade de Medicina da Universidade
More informationOutcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers
Tang et al. (2017) 7:653 DOI 10.1038/s41408-017-0030-y CORRESPONDENCE Outcomes of patients with peripheral T-cell lymphoma in first complete remission: data from three tertiary Asian cancer centers Open
More informationPatterns of Care in Medical Oncology. Follicular Lymphoma
Patterns of Care in Medical Oncology Follicular Lymphoma CASE 1: A 72-year-old man with multiple comorbidities including COPD/asthma presents with slowly progressive cervical adenopathy. Bone marrow biopsy
More informationA Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by. Thalidomide for Angioimmunoblastic T-cell Lymphoma. An NCRI Clinical Trial.
A Phase II Clinical Trial of Fludarabine and Cyclophosphamide Followed by Thalidomide for Angioimmunoblastic T-cell Lymphoma. An NCRI Clinical Trial. CRUK number C17050/A5320 William Townsend 1, Rod J
More informationHave we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES!
Have we moved beyond EPOCH for B-cell non-hodgkin lymphoma? YES! Christopher Flowers, MD, MSc Associate Professor Director, Lymphoma Program Department of Hematology and Oncology Emory School of Medicine
More informationNew Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders
New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus
More informationResearch Article Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell Lymphoma Patients
Cancer Research, Article ID 982080, 7 pages http://dx.doi.org/10.1155/2014/982080 Research Article Impact of Immunochemotherapy-Related Hepatic Toxicity on the Outcome of HCV-Positive Diffuse Large B-Cell
More informationHigh incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing regimens
original article 20: 309 318, 2009 doi:10.1093/annonc/mdn629 Published online 7 October 2008 High incidence of false-positive PET scans in patients with aggressive non-hodgkin s lymphoma treated with rituximab-containing
More informationThe Clinical Characteristics and Treatment Response of Patients with Low Grade Non-Hodgkin Lymphoma
The Egyptian Journal of Hospital Medicine (January 2019) Vol. 74 (4), Page 789-796 The Clinical Characteristics and Treatment Response of Patients with Low Grade Non-Hodgkin Lymphoma Ahmed Yosry El-Agamawi,
More informationB Cell Lymphoma: Aggressive
B Cell Lymphoma: Aggressive UpToDate: Introduction: Risk Factors: Biology: Symptoms: Diagnosis: Ibrutinib approved for mantle cell lymphoma as 2nd line therapy. - Aggressive lymphomas are a group of malignant
More informationMANTLE CELL LYMPHOMA
MANTLE CELL LYMPHOMA CLINICAL CASE PRESENTATION Martin Dreyling Medizinische Klinik III LMU München Munich, Germany esmo.org Multicenter Evaluation of MCL Annency Criteria fulfilled event free interval
More informationLymphomas in Prof Paul Ruff Division of Medical Oncology
Lymphomas in 2010 Prof Paul Ruff Division of Medical Oncology Most Common Lymphomas: ~90% B-cell and ~10% T-cell T lymphoblastic: 2% Marginal zone, nodal: 2% Other: 9% Burkitt: 2% Anaplastic large cell:
More informationHIV ASSOCIATED LYMPHOMA. Dr N Rapiti
HIV ASSOCIATED LYMPHOMA Dr N Rapiti HIV ASSOCIATED LYMPHOMA: OVERVIEW Classification Pathogenesis Prognosis cart Chemotherapy/Radiotherapy/SCT Supportive CASE 40 yr old male, Mr BM, p/w Symptomatic anemia
More informationOriginal Article. Introduction
Original Article Radiat Oncol J 217;35(4):317-324 https://doi.org/1.3857/roj.217.451 pissn 2234-19 eissn 2234-3156 Treatment results of radiotherapy following CHOP or R-CHOP in limited-stage head-and-neck
More informationThe case against maintenance rituximab in Follicular lymphoma. Jonathan W. Friedberg M.D., M.M.Sc.
The case against maintenance rituximab in Follicular lymphoma Jonathan W. Friedberg M.D., M.M.Sc. Follicular lymphoma: What are goals of treatment? Change natural history of disease: Decrease transformation
More informationJournal of American Science 2016;12(6)
Role of reduced dose CHOP with Rituximab plus involved field radiotherapy in treatment of early stage diffuse large B cell lymphoma in elderly patients Lobna A. Abdelaziz 1, Reham A. Salem 1, Nabila Hefzi
More informationProfessor Mark Bower
BHIVA AUTUMN CONFERENCE 2012 Including CHIVA Parallel Sessions Professor Mark Bower Chelsea and Westminster Hospital, London COMPETING INTEREST OF FINANCIAL VALUE > 1,000: Speaker Name Statement Mark Bower
More informationCARE at ASH 2014 Lymphoma. Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre
CARE at ASH 2014 Lymphoma Dr. Diego Villa Medical Oncologist British Columbia Cancer Agency Vancouver Cancer Centre High-yield lymphoma sessions Sat, Dec 6 th Sun, Dec 7 th Mon, Dec 8 th EDUCATIONAL SESSIONS
More informationORIGINAL ARTICLE. Keywords Relapse/refractory. DLBCL. Immunochemotherapy. Introduction
Ann Hematol (2015) 94:803 812 DOI 10.1007/s00277-014-2271-1 ORIGINAL ARTICLE Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy
More informationRelapsed/Refractory Hodgkin Lymphoma
Relapsed/Refractory Hodgkin Lymphoma Anas Younes, MD Chief, Lymphoma Service Memorial Sloan-Kettering Cancer Center New York, New York, United States Case Study 32-year-old woman was diagnosed with stage
More informationThis is a controlled document and therefore must not be changed or photocopied L.80 - R-CHOP-21 / CHOP-21
R- / INDICATION Lymphoma Histiocytosis Omit rituximab if CD20-negative. TREATMENT INTENT Disease modification or curative depending on clinical circumstances PRE-ASSESSMENT 1. Ensure histology is confirmed
More informationJonathan W Friedberg, MD, MMSc
I N T E R V I E W Jonathan W Friedberg, MD, MMSc Dr Friedberg is Professor of Medicine and Oncology and Chief of the Hematology/Oncology Division at the University of Rochester s James P Wilmot Cancer
More informationAggressive lymphomas ASH Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV
Aggressive lymphomas ASH 2015 Dr. A. Van Hoof A.Z. St.Jan, Brugge-Oostende AV CHOP 1992 2002 R-CHOP For DLBCL High dose chemo With PBSCT Aggressive lymphomas 1.DLBCL 2.Primary Mediastinal Lymphoma 3.CNS
More informationHighlights of ICML 2015
Highlights of ICML 2015 Jonathan W. Friedberg M.D. Director, James P. Wilmot Cancer Center Statistics, ICML 2015: a global meeting Almost 3700 participants. 90 countries represented. Attendees: USA 465
More informationR/R DLBCL Treatment Landscape
An Updated Analysis of JULIET, a Global Pivotal Phase 2 Trial of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Abstract S799 Borchmann P, Tam CS, Jäger U,
More informationDoes the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
Annals of Hematology (2018) 97:2129 2135 https://doi.org/10.1007/s00277-018-3437-z ORIGINAL ARTICLE Does the omission of vincristine in patients with diffuse large B cell lymphoma affect treatment outcome?
More informationOriginal Article. Abstract
Original Article Prognostic value of pre- and post-transplantation 18 F- fluorodeoxyglucose positron emission tomography results in non- Hodgkin lymphoma patients receiving autologous stem cell transplantation
More informationDr. A. Van Hoof Hematology A.Z. St.Jan, Brugge. ASH 2012 Atlanta
Dr. A. Van Hoof Hematology A.Z. St.Jan, Brugge ASH 2012 Atlanta DLBCL How to improve on R-CHOP What at relapse Mantle cell lymphoma Do we cure patients Treatment at relapse Follicular lymphoma Watch and
More informationConflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center
What Is Personalized Medicine For Patients With Lymphoma? Conflict of Interest Disclosure Form NAME :James O. Armitage, M.D AFFILIATION: University of Nebraska Medical Center DISCLOSURE I have no potential
More information1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes on the next page
COME HOME Non-Hodgkin pathway development worksheet, v6 September 2014 1. Please review the following table, make any changes you think are necessary and highlight those changes. Feel free to put notes
More informationOverview of Lymphoma Clinical Trials
Overview of Lymphoma Clinical Trials Dr Pam McKay Beatson West of Scotland Cancer Centre Lymphoma Action Patient Conference September 2018 Clinical trials medical research involving human participants
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationHow I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES
How I approach newly diagnosed Follicular Lymphoma patients with advanced stage? Professeur Gilles SALLES How I Choose First Line Treatment in Follicular Lymphoma in 2017? 1. How do I take into account
More informationMantle Cell Lymphoma
Mantle Cell Lymphoma Clinical Case A 56 year-old woman complains of pain and fullness in the left superior abdominal quadrant for the last 8 months. She has lost 25 kg, and lately has had night sweats.
More informationClinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma. Reference: NHS England 1630
Clinical Commissioning Policy Proposition: Bendamustine with rituximab for first line treatment of mantle cell lymphoma Reference: NHS England 1630 1 First published: TBC Prepared by NHS England Specialised
More informationMANAGEMENT OF LYMPHOMAS
MANAGEMENT OF LYMPHOMAS Challenges & Recommendations F. Chite Asirwa, MD. Internal Medicine Physician Medical Oncologist & Hematologist Director-AMPATH Oncology & Hematology @Kenya Physicians Association
More informationWhat is the best approach to the initial therapy of PTCL? standards of treatment? Should all
What is the best approach to the initial therapy of PTCL? standards of treatment? hould all Jia Ruan, M.D., Ph.D. Center for Lymphoma and Myeloma Weill Cornell Medical College New York Presbyterian Hospital
More informationSEQUENCING FOLLICULAR LYMPHOMA
SEQUENCING FOLLICULAR LYMPHOMA Thomas E. Witzig, MD October 24, 2015 Disclosures All presenters were independently selected by the organizing committee. Those presenters who disclosed affiliations or financial
More informationAggressive B and T cell lymphomas: Treatment paradigms in 2018
Aggressive B and T cell lymphomas: Treatment paradigms in 2018 John P. Leonard M.D. Richard T. Silver Distinguished Professor of Hematology and Medical Oncology Associate Dean for Clinical Research Associate
More informationASCO abstract June 2007 :Othieno-Abinya NA, Abwao HO, Kiarie GW)
Inferior outcome of poor prognostic phenotype non- Hodgkin s lymphoma treatment among HIV positive patients compared with HIV negative counterparts in the HAART era. (ASCO abstract June 2007 :Othieno-Abinya
More informationUpdate: Chronic Lymphocytic Leukemia
ASH 2008 Update: Chronic Lymphocytic Leukemia Improving Patient Response to Treatment with the Addition of Rituximab to Fludarabine-Cyclophosphamide ASH 2008: Update on chronic lymphocytic leukemia CLL-8
More informationAngioimmunoblastic T-cell lymphoma: nobody knows what to do...
Angioimmunoblastic T-cell lymphoma: nobody knows what to do... Felicitas Hitz, Onkologie/Hämatologie St.Gallen SAMO Lucerne 17.9.2011 : Problems PTCL are rare diseases with even rarer subgroups Difficulte
More informationThe Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page
The Egyptian Journal of Hospital Medicine (October 2017) Vol.69(1), Page 1668-1673 Role of Surveillance CT in Detection of Pre-Clinical Relapse in Patients with B- Cell lymphoma: A Retrospective Study
More informationMantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents
Mantle Cell Lymphoma New scenario and concepts in front-line treatment for young pa:ents Anas Younes, M.D. Chief, Lymphoma Service Memorial Sloan-Ke=ering Cancer Center Friday March 16, 2018: 11:15-11:30
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationBACKGROUND AND RATIONALE
SYNOPSIS Observational study on the use of B cell receptor kinase inhibitors and BCL2 antagonists prior to allogeneic hematopoietic stem cell transplantation for B cell malignancies: A joint project of
More informationAdvanced stage HL The old and new match: BEACOPP
27.03.2015 1 Advanced stage HL The old and new match: BEACOPP Peter Borchmann German Hodgkin Study Group University of Cologne, Germany Which answer is wrong? For patients with advanced stage HL, treatment
More informationORIGINAL ARTICLE. Annals of Oncology 28: , 2017 doi: /annonc/mdx128 Published online 7 April 2017
Annals of Oncology 28: 54 546, 27 doi:.93/annonc/mdx28 Published online 7 April 27 ORIGINAL ARTICLE Outcome of elderly patients with diffuse large B-cell lymphoma treated with R-CHOP: results from the
More informationONCOLOGY LETTERS 14: , 2017
ONCOLOGY LETTERS 14: 3803-3808, 2017 Upfront high dose chemotherapy combined with autologous stem cell transplantation: Potential survival benefit for patients with high risk diffuse large B cell lymphoma
More informationImproving Outcomes for Patients with Diffuse Large B-Cell Lymphoma
CA CANCER J CLIN 2010;60:393 408 Improving Outcomes for Patients with Diffuse Large B-Cell Lymphoma Christopher R. Flowers, MD, MS 1 ; Rajni Sinha, MD, MRCP 2 ; Julie M. Vose, MD 3 Abstract Diffuse large
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More information